From bench to bedside: translating novel-target ADCs against treatment-resistant tumors

Lauren Coyle, Launch Commissioning Editor, Bioconjugate Insights, speaks with Valerie Vanhooren, Co-Founder and CEO, Ona Therapeutics, about translating first-in-class ADCs from bench to bedside, including target validation, resistance biology, linker-payload strategy, and the company culture that sustains high-risk, high-gain drug development.

Authors

Publication Details

Journal
Bioconjugation Insights
Published
2026-09-29
DOI
https://doi.org/10.18609/bci.2026.028
Primary Topic
PARP inhibition in cancer therapy
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
article

From bench to bedside: translating novel-target ADCs against treatment-resistant tumors

Valerie Vanhooren
Bioconjugation Insights
PARP inhibition in cancer therapy
article

From bench to bedside: translating novel-target ADCs against treatment-resistant tumors

Valerie Vanhooren
article en

Abstract

Lauren Coyle, Launch Commissioning Editor, Bioconjugate Insights, speaks with Valerie Vanhooren, Co-Founder and CEO, Ona Therapeutics, about translating first-in-class ADCs from bench to bedside, including target validation, resistance biology, linker-payload strategy, and the company culture that sustains high-risk, high-gain drug development.

Bioconjugation InsightsVol. 1(6)
Openalex Percentile: Top 15%
PARP inhibition in cancer therapy
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

From bench to bedside: translating novel-target ADCs against treatment-resistant tumors — Valerie Vanhooren · Bioconjugation Insights (2026) | TGRS Research Map | TGRS